Nuvectis Pharma ($NVCT) Insider Trading & Smart Money Activity
Nuvectis Pharma, Inc. ($NVCT) has 7 insider trades and 3 analyst ratings on file. In the last 12 months on the open market, 2 insiders bought ($1.17M) and no insider sold, net +$1.17M.
- Insider buyers (12 mo)
- 2
- Insider sellers (12 mo)
- 0
- Net insider $ (12 mo)
- +$1.17M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 0
- Analyst ratings on file
- 3
NVCT insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 2 · $1.17M | 0 | 0 / 0 | 0 / 0 |
| Q3 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All NVCT insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Mosseri Marlio Charles | Buy (Open-market buy) | 50K sh | $916K | +4.4% | +23.8% | Read | ||||
| Insider | Ron BentsurChairman & CEO | Buy (Open-market buy) | 12.50K sh | $250K | +4.4% | +23.8% | Read | ||||
| Analyst | HC Wainwright | Reiterates to buy | PT $39 | +72.6% | +16.7% | Read | |||||
| Analyst | HC Wainwright | Reiterates to buy | PT $13 | +54.3% | +72.2% | Read | |||||
| Analyst | HC Wainwright | Reiterates to buy | PT $13 | +54.3% | +72.2% | Read | |||||
| Insider | Oliviero James III | Buy (Grant or award) | 35K sh | +31.5% | +75.5% | — | |||||
| Insider | Oliviero James III | Buy (Grant or award) | 35K sh | +31.5% | +75.5% | — | |||||
| Insider | Matthew Kaplan | Buy (Grant or award) | 35K sh | +31.5% | +75.5% | — | |||||
| Insider | Kenneth Hoberman | Buy (Grant or award) | 35K sh | +31.5% | +75.5% | — | |||||
| Insider | Kenneth Hoberman | Buy (Grant or award) | 35K sh | +31.5% | +75.5% | — |
1W / 1M / 6M = how NVCT moved from the trade or filing date.
Insider trading in NVCT: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Mosseri Marlio Charles | 1 | +$916K | Jun 30, 2026 | ||
| Ron Bentsur | Chairman & CEO | 1 | +$250K | Jun 30, 2026 | |
| Oliviero James III | 2 | — | Jun 11, 2026 | ||
| Kenneth Hoberman | 2 | — | Jun 11, 2026 | ||
| Matthew Kaplan | 1 | — | Jun 11, 2026 |
Analyst ratings on NVCT
Frequently asked questions
Are NVCT insiders buying or selling?
Over the last 12 months 2 insiders made 2 open-market purchases worth $1.17M and 0 insiders made 0 open-market sales worth $0, a net +$1.17M.
What is the latest insider trade in NVCT?
Mosseri Marlio Charles filed a buy (open-market buy) of 50K sh worth $916K on Jun 30, 2026.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.